AATec Medical receives 4 million euros

AATec Medical is developing a new therapeutic option for patients with non-cystic bronchiectasis - now the company is securing fresh capital for the next development steps.

Munich, April 16, 2025 - The Munich-based biotechnology company AATec Medical GmbH has raised four million euros in a financing round. The money comes from the German Federal Agency for Springboard Innovations (SPRIND) as well as from wealthy private individuals, industry experts and family offices. AATec intends to use the fresh capital to further advance its ATL-105 drug project for the treatment of chronic lung diseases.

ATL-105 to reach clinical maturity by 2026

The aim of the current financing is to prepare ATL-105 for clinical use. This involves so-called "IND-enabling" activities - i.e. preparatory steps for the approval of clinical trials. The drug is to be tested on patients for the first time from 2026.

ATL-105 is an inhalable drug based on recombinantly produced alpha-1-antitrypsin (AAT). This active ingredient has anti-inflammatory, immunomodulating and anti-infective properties. The first target disease is non-cystic bronchiectasis (NCFB), a chronic inflammation of the airways for which there is currently no causal therapy.

Great need for new treatment options

Millions of people worldwide are affected by NCFB. According to AATec, more than three million people in Western countries suffer from this disease. Until now, treatment has been limited to alleviating symptoms, usually with antibiotics, macrolides and respiratory therapy. ATL-105 is intended to offer a new option here, which acts directly on the foci of inflammation in the lungs. Targeted inhalation should enable high efficacy with minimal side effects.

Strong support from SPRIND

SPRIND Innovation Manager Sigrid Koeth praises AATec's technology: "We are looking for approaches that have the potential to make a fundamental difference. The use of recombinant alpha-1 antitrypsin could be one such approach." The Federal Agency sees this development as an important signal for the future of public health and the resilience of the healthcare system.

Successful preclinical tests

According to AATec, preclinical studies have already confirmed the safety and broad therapeutic potential of ATL-105. The results to date show good tolerability and a targeted effect on key disease mechanisms in inflammatory lung diseases. The company plans to build a product platform with ATL-105 that can also be used for other respiratory diseases.

AATec Medical was founded by an interdisciplinary team with extensive experience in clinical research and biopharmaceutical development. The company is developing a platform technology based on alpha-1-antitrypsin for the treatment of inflammatory respiratory diseases, infections and rare diseases. With the financing now completed, AATec has reached an important milestone in its preparations for clinical trials. The start-up thus joins a growing number of young biotech companies that want to advance the field of respiratory therapies with innovative approaches.